Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Merck Animal Health, a division of Merck & Co., Inc. (NYSE:MRK), has received FDA approval for the expanded use of BRAVECTO® Chews for Dogs, now treating and controlling infestations of the Asian longhorned tick. This is the first product in the U.S. addressing this invasive tick species, which poses health risks to pets and humans. The approval enhances BRAVECTO's comprehensive parasite protection portfolio, underscoring Merck's commitment to innovative veterinary solutions. With over 250 million doses distributed since 2014, BRAVECTO aims to offer pets prolonged protection against various parasites.
Merck (NYSE: MRK) has announced the cessation of the Phase 3 KEYNOTE-991 trial for KEYTRUDA, its anti-PD-1 therapy, in combination with enzalutamide and androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). This decision follows a recommendation from an independent Data Monitoring Committee after an interim analysis revealed no improvement in overall survival or radiographic progression-free survival compared to the control group. Although no new safety signals were identified, the combination treatment exhibited a higher rate of Grade 3-5 adverse events. Merck remains committed to developing new treatment options for prostate cancer.
Merck (NYSE: MRK) announced positive results from the Phase 3 KEYNOTE-966 trial, demonstrating that KEYTRUDA, in combination with chemotherapy, significantly improves overall survival for patients with advanced biliary tract cancer compared to chemotherapy alone. The safety profile was consistent with earlier studies. With biliary tract cancer's poor prognosis, highlighted by only 5% to 15% five-year survival rates, these results offer hope for new treatment options. Merck plans to present results at a medical meeting and submit them to regulatory authorities while continuing to explore KEYTRUDA's use in various gastrointestinal cancers.
Merck (NYSE: MRK) has declared a quarterly dividend of $0.73 per share for Q2 2023. Shareholders of record will receive this payment on April 10, 2023, with the record date being March 15, 2023. Merck aims to leverage leading-edge science to improve lives worldwide, boasting over 130 years in the biopharmaceutical industry. The company emphasizes research and innovation in health solutions for both people and animals, while fostering a diverse and inclusive workforce.
Perceiv AI has been chosen for the inaugural cohort of the Merck Digital Sciences Studio (MDSS), receiving funding and mentorship from Merck (NYSE: MRK), Northpond Ventures, and McKesson Ventures. This selection, announced on January 17, 2023, is a significant milestone for Perceiv AI, highlighting their innovative prognostic platform that integrates multimodal data to address neurodegenerative diseases. The MDSS program aims to enhance drug discovery and development through collaborations and access to advanced technology. Perceiv AI plans to expand its ForesightTM platform to develop biomarkers for conditions like Alzheimer's disease.
Summary not available.
Merck (NYSE: MRK) has successfully completed its cash tender offer for all outstanding shares of Imago BioSciences (NASDAQ: IMGO) at $36.00 per share. The offer expired on January 10, 2023, with 31,307,028 shares validly tendered, representing approximately 89.2% of Imago’s total outstanding shares. Following the acquisition, Imago will merge into Merck's subsidiary, becoming a wholly owned subsidiary, and its shares will be delisted from Nasdaq.
Summary not available.
Merck (NYSE: MRK) will host its fourth-quarter and full-year 2022 earnings call on February 2 at 8:00 a.m. ET. Executives will review company performance and future outlook. The call will be accessible via a weblink and through phone lines at (888) 769-8514 in the U.S. and (517) 308-9208 internationally. A replay will also be available on Merck's website.
Merck (NYSE: MRK) has announced that Robert M. Davis, CEO, and Dr. Dean Y. Li, President of Merck Research Laboratories, will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 5:15 PM PT / 8:15 PM ET. A live audio webcast of the presentation will be available for investors and the public.
Merck is committed to advancing healthcare through research and innovation, focusing on developing medicines and vaccines to improve lives globally.